Clinical Trials
18 trialsNCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT05427487 2026-03-25
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
Phase 1 Recruiting
NCT05718219 2025-08-13
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05504278 2025-01-27
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Recruiting
NCT05088967 2024-01-16
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT05164458 2023-12-28
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT05119998 2023-08-18
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05026593 2023-07-19
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04672356 2023-06-22
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04672369 2023-06-22
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03545971 2023-02-28
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04177290 2023-02-27
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05118334 2023-02-23
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03758001 2023-02-22
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04861948 2022-10-04
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT04427774 2021-07-20
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT03568539 2021-06-01
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed